Versartis, Inc. (VSAR) Files Form 4 Insider Selling : Paul Westberg Sells 1,430 Shares

Versartis, Inc. (VSAR): Paul Westberg , Sr. VP, Business Development of Versartis, Inc. sold 1,430 shares on Apr 21, 2016. The Insider selling transaction was reported by the company on Apr 25, 2016 to the Securities and Exchange Commission. The shares were sold at $9.68 per share for a total value of $13,842.40 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jan 4, 2016, Paul Westberg (Sr. VP, Business Development) sold 362 shares at $12.44 per share price.On Jan 4, 2016, Joshua T Brumm (Chief Financial Officer) sold 990 shares at $12.44 per share price.Also, On Nov 13, 2015, R Scott Greer (director) purchased 10,000 shares at $10.16 per share price.On Apr 16, 2015, Jeffrey L Cleland (President and CEO) sold 8,000 shares at $20.13 per share price.

Versartis Inc: On Friday, Apr 22, 2016 heightened volatility was witnessed in Versartis Inc which led to swings in the share price. The shares opened for trading at $10.16 and hit $10.35 on the upside , eventually ending the session at $10.25, with a gain of 1.28% or 0.13 points. The heightened volatility saw the trading volume jump to 77,492 shares. The 52-week high of the share price is $22.655 and the company has a market cap of $302 M . The 52-week low of the share price is at $6.17.

Versartis Inc Money Flow Index Chart

Versartis Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone VRS-317 for growth hormone deficiency (GHD) an orphan disease. The Company’s products include VRS-317 and XTEN Technology. VRS-317 combines the rhGH amino acid sequence utilized in rhGH products with a half-life extension technology XTEN to enable less frequent administration. The Company has initiated a Phase III clinical study of VRS-317 in pediatric growth hormone deficient patients. XTEN is a recombinant polypeptide that when genetically fused to a therapeutic payload of interest extends the in vivo half-life of these peptides and proteins in a tunable manner.

Leave a Reply

Versartis Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Versartis Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.